Emergent BiosolutionsEBS
EBS
About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Employees: 1,600
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
20% more capital invested
Capital invested by funds: $220M [Q2] → $265M (+$44.1M) [Q3]
6% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 31
1% less funds holding
Funds holding: 141 [Q2] → 140 (-1) [Q3]
1.2% less ownership
Funds ownership: 61.67% [Q2] → 60.47% (-1.2%) [Q3]
11% less call options, than puts
Call options by funds: $7.37M | Put options by funds: $8.31M
40% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 50
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
7%
upside
Avg. target
$13.50
20%
upside
High target
$15
33%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 135 / 327 met price target | 33%upside $15 | Buy Reiterated | 21 Jan 2025 |
Benchmark Robert Wasserman 65% 1-year accuracy 32 / 49 met price target | 7%upside $12 | Buy Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 6 articles about EBS published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Africa CDC's support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo.
Positive
Seeking Alpha
2 weeks ago
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock.
Neutral
GlobeNewsWire
2 weeks ago
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals' KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 This six-year agreement complements and strengthens Emergent's mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education.
Neutral
GlobeNewsWire
2 weeks ago
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus.
Neutral
GlobeNewsWire
3 weeks ago
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST.
Neutral
GlobeNewsWire
3 weeks ago
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD).
Positive
The Motley Fool
1 month ago
Why Emergent BioSolutions Stock Blasted Higher Today
An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.
Positive
Zacks Investment Research
1 month ago
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
Negative
The Motley Fool
1 month ago
Why Emergent BioSciences Stock Plummeted Today
Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities.
Negative
Seeking Alpha
2 months ago
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox.
Charts implemented using Lightweight Charts™